Savara (SVRA) announced that it has resubmitted the Molbreevi BLA to the FDA, with Fujifilm as the drug substance manufacturer. The Molbreevi BLA submission is seeking approval for the treatment of autoimmune PAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli. The company has requested Priority Review of the application.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- Savara announces EPO intention to grant Molbreevi patent application
- Savara’s MOLBREEVI: A Promising Solution for aPAP with Blockbuster Potential
- Savara rumor highlighted in Betaville blog
- Savara issues patent for Molbreevi from European Patent Office
- Savara’s MOLBREEVI: Promising Potential in APAP Market with Strategic Expert Engagement